Business Context and Reporting Period
Company: ImmuCell Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1999
Business Overview: ImmuCell operates primarily in the animal health sector, focusing on the dairy and beef industries. Its core products include "First Defense" and the "Kamar Heatmount Detector." The company also maintains a Research and Development (R&D) segment and holds an investment in a joint venture, AgriCell Company, LLC, focused on bovine lactoferrin production.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Total Revenues | $1,403,600 | $1,335,034 |
| Net Profit | $253,899 | $219,261 |
| Operating Income | $251,157 | $205,169 |
| Net Cash from Operations | $63,312 | $461,098 |
| Cash and Equivalents (Ending) | $1,571,163 | $1,404,781 |
| Total Debt (Current + Long Term) | $466,295 | N/A (Refinanced in 1998) |
| Working Capital | $2,115,894 | N/A |
| Stockholders' Equity | $2,501,495 | N/A |
Margins: Gross margin on product sales was 57% for Q1 1999, down slightly from 58% in Q1 1998. R&D expenses represented 17% of total revenues in Q1 1999.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by approximately 5% ($68,566) compared to Q1 1998. Product sales rose 4% ($56,326), driven by a 6% increase in sales of core products (First Defense and Kamar Heatmount Detector).
- Profitability: Net profit increased by 16% ($34,638) year-over-year. This was achieved despite higher R&D costs, due to significant reductions in General and Administrative (G&A) expenses (down 23%) and Sales and Marketing expenses (down 6%).
- Cash Flow: Net cash provided by operating activities decreased significantly to $63,312 from $461,098 in the prior year. This decline was primarily due to a $256,291 increase in accounts receivable and a $130,081 decrease in accrued expenses.
- Inventory: Total inventories decreased by $117,954, reflecting a reduction in work-in-process and raw materials.
Guidance, Outlook, and Risks
- Strategic Shift: Management has shifted R&D focus from human health products to animal health products to foster growth and reduce funding requirements. The company anticipates recording a profit for the full year 1999, contrasting with the net loss recorded for the full year 1998.
- Joint Venture: Sales from the AgriCell joint venture (lactoferrin) remain significantly below expectations due to financial crises in South Korea and Japan. A non-cash charge of $123,000 was taken against this investment in 1998.
- Liquidity: The company believes it has sufficient capital resources to meet working capital requirements for the next 12 months. Approximately $191,000 remains available under a Phase II Small Business Innovation Research grant.
- Year 2000 Issue: The company estimates costs to address Year 2000 compliance will not exceed $23,000. New software and hardware have been installed, with implementation continuing through Q2 1999.
- Risks: Forward-looking statements are subject to risks regarding product development delays, regulatory approvals, and market competition.
Investor Verification Checklist
- Accounts Receivable: Verify the collectability of the $256,291 increase in receivables, which significantly impacted operating cash flow.
- Joint Venture Valuation: Assess the recoverability of the $97,134 investment in AgriCell given the continued underperformance in Asian markets.
- Debt Covenants: Review the terms of the $466,295 mortgage loan (8.62% interest) and ensure compliance with covenants given the shift in R&D spending.
- Grant Utilization: Confirm the timeline and spending requirements for the remaining $191,000 in Small Business Innovation Research grant funds.
- Product Concentration: Note that 96% of product sales rely on two specific products (First Defense and Kamar Heatmount Detector), creating concentration risk.